STAAR Surgical (STAA) Stock May Be 14% Undervalued On Cash Flow

STAAR Surgical has seen its share price move around over the years, and the record over longer periods raises a clear question for anyone looking at the stock today. Is the current price really supported by the cash the business can generate over time, based on a Discounted Cash Flow (DCF) view of those cash flows?

• Over the past 5 years the share price has fallen 77.8%, which puts the focus squarely on whether the cash flow outlook now lines up with where the stock trades.
• The business relies on translating its vision-correction products into durable cash generation, so execution on pricing, production costs, and reinvestment needs can materially shape the cash flows that feed into any intrinsic value estimate.
• What if you looked at STAAR Surgical through its sales instead? See why STAAR Surgical's 3.9x P/S tells a different valuation story.

For investors, the debate is whether STAAR Surgical's current share price is justified by the cash flows implied in a Discounted Cash Flow (DCF) view of the business.

If you are questioning whether STAAR Surgical's recent share price path and cash flows line up, it can help to compare that picture with a focused list of 39 high quality undervalued stocks as another research starting point.

Is STAAR Surgical a Bargain on Cash Flow?

The Discounted Cash Flow (DCF) model here focuses on the cash that STAAR Surgical can return to shareholders over time. Latest twelve month free cash flow sits at about $9 million, so the valuation leans heavily on expectations that future cash generation improves from this recent base rather than staying stuck at current levels.

Analyst and model projections used in this 2 Stage Free Cash Flow to Equity approach point to growing annual free cash flows in dollar terms over the coming decade, transitioning from specific analyst inputs in the near years to more tempered estimates further out. When those projected cash streams are discounted back and compared with the current share price of $25.21, the DCF output suggests the estimated intrinsic value comes in modestly above where the stock trades today. This indicates that, based on this model, the market is not fully crediting the cash flow profile implied by these projections. Find out what STAAR Surgical could be worth using our Discounted Cash Flow (DCF) estimate.

The STAAR Surgical Narrative: What Would Justify Today's Price?

Simply Wall St Narratives for STAAR Surgical link the valuation question above to concrete assumptions about the company’s future cash generation and profitability, so you can see what kind of earnings path would need to play out for the stock to look materially cheaper or more expensive than today’s price. Rather than leaving you with a single model output, they explain the future that figure rests on so you can watch how reality compares over time.

Bulls and bears on STAAR Surgical are looking at the same refractive lens business and reaching very different conclusions about how much is already priced in.

Bull case: 10% undervalued

"The Nidau, Switzerland facility is planned to supply all EVO and EVO+ lenses shipped to China by the end of 2026, which would remove China tariffs on those products…"

Discover why this Narrative puts STAAR Surgical at 10% undervalued.

Bear case: 33% overvalued

"The recent announcement of an investigation into possible breaches of fiduciary duties by certain STAAR officers and directors introduces governance and legal uncertainty…"

Explore why this Narrative puts STAAR Surgical at 33% overvalued.

Before acting on STAAR Surgical's valuation, one more factor deserves attention

Price targets and cash flow models only tell part of the story, because the track record and pay packets of the people steering STAAR Surgical can heavily influence how those numbers play out. See who runs STAAR Surgical and how they are paid.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com